Studies of ex vivo muscle cell autophagy flux, leucocyte mitochondrial function and oxylipins, specifically prostaglandin E2 (PGE2) in critically ill patients during admission to an intensive care unit (ICU).
ID
Source
Brief title
Condition
- Metabolism disorders NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Autophagy flux measured in primary human myotubes incubated for 24 hours with
serum from ICU patients, mitochondrial function in peripheral blood mononuclear
cells (PBMCs) measured by functional respirometry (oroboros) and prostaglandin
E2 (PGE2) levels as measured by LCMSMS.
Secondary outcome
- Investigate the localization of autophagy flux and of autophagy changes at
different time points
- To determine if and how parameters of the hypermetabolic inflammatory state
are related to the progression of mitochondrial function in IC patients
- To determine if and how progression of mitochondrial function is related to
physical performance and clinical outcomes in IC patients
- To examine how mitochondrial dynamics change over time and how this is
associated with mitochondrial function in IC patients
- Investigate the oxylipin profile measured by LCMSMS and lipopolysaccharide
(LPS) levels
- To examine how prostaglandin levels are related to inflammatory cytokine
levels.
- To determine how oxylipin levels are associated with changes in autophagy and
mitochondrial function and vise versa.
Background summary
Hospital Gelderse Vallei's close ties with Wageningen University and the
Karolinska Institute provide the opportunity to investigate the proposed
association between protein supply and functional disease outcome at the basal
level by measuring autophagy flux, mitochondrial function and prostaglandin
levels. This study will examine the explanations behind the associations.
Study objective
Studies of ex vivo muscle cell autophagy flux, leucocyte mitochondrial function
and oxylipins, specifically prostaglandin E2 (PGE2) in critically ill patients
during admission to an intensive care unit (ICU).
Study design
This study consists of a combination of 3 single-centre observational cohort
studies in patients participating in the PRECISe trial.
Study burden and risks
The included patients will already have an arterial catheter in situ;
therefore, the blood draw in this case poses minimal risk and is completely
painless. There are no direct benefits for the included patients. However, this
study may provide important information that will add value to the results of
the PRECISe trial. In this way, mechanisms that have not been studied before
may be revealed and may contribute to a better understanding about autophagy
flux, metabolism, and metabolism in IC patients.
Willy Brandtlaan 10
Ede 6716RP
NL
Willy Brandtlaan 10
Ede 6716RP
NL
Listed location countries
Age
Inclusion criteria
1. Patient partipates in PRECISe trial
2. Adult >= 18 years-old admitted to the ICU
3. Unplanned ICU admission
4. Invasive mechanical ventilation initiated <24 hours of ICU admission
5. Expected ICU stay on ventilator support of >= 3 days
Exclusion criteria
1. Contraindication for enteral nutrition
2. Moribund or expected withholding of treatment
3. Kidney failure with *no dialysis*-code on admission
4. Hepatic encephalopathy
5. Body-mass index <18 kg/m²
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL78150.068.21 |